Press Releases

 
Press Releases
Date Title and Summary View
Aug 14, 2012 SALT LAKE CITY, Aug. 14, 2012 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc. (Nasdaq:MYGN) today announced results for its fourth quarter and fiscal year ending June 30, 2012. Revenue for the fourth fiscal quarter increased 24 percent over the same period in the prior year to $133.0 million and resulted in fiscal year 2012 revenue of $496.0 million, an ...
Jul 26, 2012 SALT LAKE CITY, July 26, 2012 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc. (Nasdaq:MYGN) today announced that it has signed an agreement with Pharma Mar, a leader in the development of marine-derived drugs. Under the agreement, Myriad will conduct BRCA 1 and BRCA 2 testing on patients to be enrolled in a Phase II clinical study of PM1183, a novel drug...
Jul 24, 2012 SALT LAKE CITY, July 24, 2012 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc. (Nasdaq:MYGN) today announced that it will issue financial results for the fourth fiscal quarter and fiscal year 2012 following the close of market on Tuesday, August 14, 2012. The Company will also host a conference call on Tuesday, August 14, 2012 at 4:30 P.M. Eastern...
Jun 6, 2012 SALT LAKE CITY, June 6, 2012 (GLOBE NEWSWIRE) -- Myriad Genetics announced today that the Company is the honorable recipient of the 2012 Charles R. Smart Visionary Award from the American Cancer Society's Salt Lake City office, a part of the Great West Division. This award is presented annually at the Society's Legacy & Leadership event to recogniz...
Jun 4, 2012 SALT LAKE CITY, June 4, 2012 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc. (Nasdaq:MYGN) announced today that a presentation entitled "Use of a Proliferation-Based mRNA Signature to Predict Outcome in Early-Stage Non-Small Cell Lung Adenocarcinoma," was presented on Sunday, June 3, 2012 at the American Society of Clinical Oncology® (ASCO) Annual M...
May 22, 2012 SALT LAKE CITY, May 22, 2012 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc. (Nasdaq:MYGN) announced today that the Company is scheduled to present at two upcoming investor conferences:   Jefferies 2012 Global Healthcare Conference in New York City, New York on June 5th at 8:30 a.m. Eastern Time; and Goldman Sachs 33rd Annual Glob...
May 16, 2012 SALT LAKE CITY, May 16, 2012 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc. (Nasdaq:MYGN) announced today the presentation of a study at the American Society of Clinical Oncology® (ASCO) Annual Meeting, including the complete results from a study titled, "Use of a proliferation-based mRNA signature to predict outcome in early-stage non-small cell l...
May 9, 2012 Salt Lake City, UT (PRWEB) May 09, 2012 Myriad Genetics (NASDAQ: MYGN) announced today that Myriad RBM, a wholly owned subsidiary of Myriad Genetics, has launched OncologyMAP® v. 2.0, a powerful research tool developed with funding and direction from the National Cancer Institute and the Cancer Prevention Research Institute of Texas. Oncolo...
May 1, 2012 SALT LAKE CITY, May 1, 2012 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc. (Nasdaq:MYGN) today announced results for its third fiscal quarter and nine months ending March 31, 2012. Revenue for the third fiscal quarter was $129.8 million, an increase of 27 percent over the $102.4 million reported in the third fiscal quarter of 2011. Earnings per diluted ...
Apr 10, 2012 SALT LAKE CITY, April 10, 2012 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc. (Nasdaq:MYGN) today announced that it will issue financial results for the third fiscal quarter following the close of market on Tuesday, May 1, 2012. The Company will also host a conference call on Tuesday, May 1, 2012 at 4:30 P.M. Eastern to review the financial resu...
Page: FirstPrevious ...
10
... NextLast
= add release to Briefcase